{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pazopanib+Hydrochloride&page=2", "query": { "intervention": "Pazopanib Hydrochloride", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pazopanib+Hydrochloride&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pazopanib+Hydrochloride&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T13:37:39.962Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02601209", "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Sarcoma", "Metastatic Leiomyosarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Myxofibrosarcoma", "Recurrent Leiomyosarcoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Synovial Sarcoma", "Recurrent Undifferentiated Pleomorphic Sarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Leiomyosarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2015-11-30", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 460, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601209" }, { "nct_id": "NCT01532687", "title": "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Undifferentiated Pleomorphic Sarcoma", "Malignant Adult Hemangiopericytoma", "Recurrent Adult Soft Tissue Sarcoma", "Sarcoma", "Stage III Adult Soft Tissue Sarcoma AJCC v7", "Stage IV Adult Soft Tissue Sarcoma AJCC v7" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2012-03-13", "completion_date": "2019-10-31", "has_results": true, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 2, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01532687" }, { "nct_id": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 140, "start_date": "2014-08-12", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 365, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180867" }, { "nct_id": "NCT00861913", "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-04-03", "completion_date": "2014-01-16", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Detroit, Michigan • Rochester, Minnesota + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861913" }, { "nct_id": "NCT00060151", "title": "GW786034 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": null, "start_date": "2002-12", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 2, "location_summary": "Durham, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060151" }, { "nct_id": "NCT03334409", "title": "Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v7", "Unresectable Renal Cell Carcinoma" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-02-16", "completion_date": "2021-03-13", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 5, "location_summary": "Peoria, Illinois • Urbana, Illinois • Rochester, Minnesota + 2 more", "locations": [ { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334409" }, { "nct_id": "NCT01767636", "title": "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma of the Collecting Ducts of Bellini", "Chromophobe Renal Cell Carcinoma", "Kidney Medullary Carcinoma", "Kidney Oncocytoma", "Metastatic Renal Cell Cancer", "Papillary Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Pazopanib Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2013-05-16", "completion_date": "2021-01-20", "has_results": true, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01767636" }, { "nct_id": "NCT00459381", "title": "Pazopanib in Treating Patients With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2007-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459381" }, { "nct_id": "NCT00450879", "title": "Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Male Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer" ], "interventions": [ { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2007-01", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450879" }, { "nct_id": "NCT01599832", "title": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2012-06", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-06-08", "last_synced_at": "2026-10-02T13:37:39.962Z", "location_count": 4, "location_summary": "Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01599832" } ] }